Table 8 Phase V 2010- Current:Natural, derivative and polymeric CDs in alliance with nanoproperties
From: Chronicle updates in cyclodextrin-based carriers for drug delivery
Sr. No. | Year | CD type/ derivative | Drug | Class of drug | System/Model | Problem of drug delivery/ result | Reference |
|---|---|---|---|---|---|---|---|
1 | 2010 | Poloxamer407 (P407)/ HP-β-CD | Fexofenadine hydrochloride | Anti-histamine | In vitro | Bioavailability enhanced | Cho et al. (2010) |
2 | 2010 | HP-β-CD and chitosan nanocarriers | Simvastatin | HMG CoA reductase inhibitors | In vitro | Controlled release | Vyas et al. (2010) |
3 | 2011 | β -CD functionalized HPG | Paclitaxel | Anti-cancer | In vitro | High loading capacity and high encapsulation efficiency burst release followed by continuous extended release | Zhang et al. (2011a) |
4 | 2011 | SBE-β-CD | Econazole nitrate | Anti-fungal | in vivo (rabbit) | Controlled released | Mahmoud et al. (2011) |
5 | 2011 | HP-β-CD, SBE-β-CD (albumin nanoparticles) | Tacrine hydrochloride | Acetylcholinesterase inhibitor | Ex vivo/ sheep nasal mucosa | Bioavailability/permeation increased | Luppi et al. (2011) |
6 | 2011 | Methyl-β-CD | Ciprofloxacin | Antibiotics | In vitro | Anti-microbial activity enhanced Sustained release | Blanchemain et al. (2011) |
7 | 2011 | β-CD Nanosponges | Resveratrol | Polyphenolic phytoalexin | In vivo (rabbit) | Enhanced permeation | Ansari et al. (2011) |
8 | 2011 | Insulin-loaded HPG-γ-CD nanoparticles | Insulin | Hormonal therapy | In vivo (rats) | Nasal insulin delivery | Zhang et al. (2011b) |
9 | 2011 | HP-β-CD | Doxycycline | Antibiotics | In vitro | Stability and sustained release | He et al. (2011) |
10 | 2012 | β-CD hydrogels | Naproxen and nabumetone naftifine and terbinafine | NSAIDs anti-fungal | In vitro | Controlled released | Machín et al. (2012) |
11 | 2012 | Methyl-β-CD | Olanzapine | Anti-psychotic drug | Study in rabbit's eye | Higher solubility, consequently, higher bioavailability | Freitas et al. (2012) |
12 | 2012 | Randomly methylated-β-CD | Benznidazole | Anti-parasitic medication | In vivo | Effective, standardized and safe drug delivery | Soares-Sobrinho et al. (2012) |
13 | 2012 | β-CD-epichlorohydrin polymer, CM-β-CD-epichlorohydrin polymer | Ketoprofen | NSAIDs | In vitro | Permeation enhancement | Cirri et al. (2012) |
14 | 2013 | β-CD-crosslinked alginate gel | Ondansetron | Anti-emetic drug | In vitro | Controlled release | Izawa et al. (2013) |
15 | 2013 | Chitosan (CS) grafted with γ-CD nanoparticles | Ketoprofen | NSAIDs | In vitro | Controlled drug release | Yuan et al. (2013) |
16 | 2013 | Mono- and multi-methacrylate substituted CD | Doxorubicin | Anti-cancer | In vitro | Enhanced doxorubicin delivery | Zhang et al. (2013) |
17 | 2013 | β-CD | p-cymene | Anti-nociceptive and anti-inflammatory effects | In vivo (mice) | Improved analgesic and anti-inflammatory effects | Quintans et al. (2013) |
18 | 2014 | β-CD-poly(ethylene glycol)-b-12 polylactide | Doxorubicin | Anti-cancer | In vitro & In vivo (mice) | Anti-tumour activity decreased cardiotoxicity | Li et al. (2015) |
19 | 2014 | β-CD | Tetracycline | Antibiotics | In vitro | Greater drug loading efficiency slower drug release | Gogoi and Chowdhury (2014) |
20 | 2014 | β-CD and HP-β-CD | Natamycin | Anti-fungal | In vitro | Increased drug released | Phan et al. (2014) |
21 | 2014 | β CD | Ciprofloxacin and prednisolone | Antibiotic & NSAID | in vitro, in vivo (in humans) | Enhanced release Control For Drug Delivery Applications | Hernandez-Montelongo et al. (2014) |
22 | 2014 | Polyacrylates functionalized with adamantane and β-CD | Doxorubicin | Anti-cancer drug | In vivo (mice) | Enhance the therapeutic effects of DOX for effectively inhibiting the tumour growth | Ang et al. (2014) |
23 | 2015 | β-CD grafted carboxymethyl chitosan hydrogels | Acetylsalicylic acid | NSAID | In vitro | Biodegradable active material with controlled drug release ability | Kono and Teshirogi (2015) |
24 | 2013 | β-CD-Gold Glyco-nanoparticles | Methotrexate | Anti-cancer | in vitro | Site-specific delivery systems | Aykac et al. (2013) |
25 | 2016 | β- CD/cellulose nanocrystals | Curcumin | Anti-cancer | In vitro | Anti-proliferative effect on colorectal and prostatic cancer cell lines | Ntoutoume et al. (2016) |
26 | 2016 | Chitosan coated magnetic nanoparticles with acrylic acid and grafted with ethylene-diamine derivative of β-CD | Curcumin | Anti-cancer | In vitro | Controlled release, increased cytotoxicity, enhancement of biocompatibility | Anirudhan et al. (2016) |
27 | 2015 | Heptakis(6-amino-6-deoxy)-β-CD | Sorafenib | Anti-cancer | In vitro | Sustained drug release | Correia et al. (2015) |
28 | 2015 | HP-β-CD | Sulfisoxazole | Anti-bacterial | In vitro | Controlled Release | Aytac et al. (2015) |
29 | 2016 | CD nanoparticles | Polyhydroxyalkanoates, poly-(lactic-co-glycolic acid) | Anti-cancer | In vitro | Controlled release | Masood (2016) |
30 | 2016 | CD-polyhydrazine degradable gels | Nicardipine | Calcium channel blockers | In vitro | Sustained release | Jalalvandi et al. (2016) |
31 | 2017 | polyβ-CD | Polylactide | Lung cancer | In vitro | Sustained drug delivery | Feng et al. (2017) |
32 | 2017 | β-CD with thermo-responsive nanogels | Dexamethasone | Anti-inflammatory | In vitro/ in vivo (human skin) | Enhanced penetration | Giulbudagian et al. (2018) |
33 | 2018 | HP-β-CD modified carboxylated single-walled carbon nanotubes | Formononetin | antiviral, antioxidant | In vitro | Slow and sustained release | Liu et al. (2018) |
34 | 2018 | β-CD grafted polypyrrole magnetic nanocomposites | Doxorubicin | Anti-cancer | In vitro | Controlled release and targeted delivery | Hong et al. (2018) |
35 | 2019 | β-CD modified with Maleic anhydride and NIPAM | Doxorubicin and Curcumin | Anti-cancer | In vivo (mice)/ In vitro | Enhanced bioavailability | Das et al. (2019) |
36 | 2019 | Biotin & arginin + HP-β-CD nanoparticles | Pacilitaxel | Anticancer | In vitro & In vivo | Increase cellular uptake | Yan et al. (2019) |
37 | 2019 | 2- HP-β-CD -PLGA-nanoparticles | Triamcinolone acetonide | Corticosteroid used in rashes, redness & swelling | In vitro/In vivo | Enhance drug penitation | Li et al. (2019) |
38 | 2019 | Folic acid (FA) + Polyethylene glycol(PEG) + β-CD nanoparticles | Doxorubicin | Liver cancer | In vitro | Enhance solubility & control drug delivery | Fan et al. (2019) |
39 | 2020 | Chitosan citric acid crosslinked with β-CD nanoparticles | Curcumin | Multiple diseases | In vitro | Increase release time | Karpkird et al. (2020) |
40 | 2021 | HP-β-CD nanofibres | Acyclovir | Antiviral | In vitro | Improve bioavailability by enhancing solubility | Celebioglu and Uyar (2021) |
41 | 2021 | 2 HP-β-CD nanofibre | Kenamycin, chloromphinicol,gentamycin, ampicillin | Antibiotics | In silico and in vitro | Enhance dissolution in oral drug delivery system | Topuz et al. (2021) |
42 | 2021 | HP-β-CD nanoemulsion | Doxibuprofen | Analgesic, Antipyretic, NSAID | In vitro | Enhance oral bioavailability | Kim et al. (2021) |
43 | 2021 | β-CD as a nanocarrier | Lenalidomide | Anticancer | Quantum chemical approach | β-CD suitable nano carrier for lenalidomide | Harati et al. (2021) |
44 | 2021 | CD nanosponge | Doxorubicin | Anticancer | In vitro & in vivo (Wistar rat) | Enhanced solubility & bioavailability | Deng et al. (2021) |
45 | 2021 | β-CD nanocomposite | In vivo (rabbit eye sclera) | Xu et al. (2021) | |||
47 | 2022 | Folate-appended-polyethylenimine-β-CD | Doxorubicin and Human telomerase reverse transcriptase-small interfering RNA | Anticancer | In vitro (Cell lines) | Co-delivery enhanced efficacy and reduced toxicity of Doxorubicin as anticancer drug | Mousazadeh et al. (2022) |
48 | 2022 | Gelatin and hyaluronic acid functionalized CD | Paclitaxel and Vit-E derivative | Anticancer | In-vivo(rats) | CD and Vit-E derivative combination to improve solubility and bioavailability of drug | Zou et al. (2022) |